Mackenzie Financial Corp Makes New $83,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Mackenzie Financial Corp Makes New $83,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT)
Mackenzie Financial Corp acquired a new position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 10,230 shares of the company's stock, valued at approximately $83,000.
麥肯齊金融公司收購了Adaptive Biotechnologies Co. 股票的新頭寸(納斯達克股票代碼:ADPT — 獲取評級)在第二季度向美國證券交易委員會提交的最新13F表文件顯示。該公司收購了該公司10,230股股票,價值約83,000美元。
Other large investors have also modified their holdings of the company. State of New Jersey Common Pension Fund D boosted its stake in shares of Adaptive Biotechnologies by 58.4% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 294,645 shares of the company's stock worth $2,384,000 after acquiring an additional 108,686 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Adaptive Biotechnologies by 61.3% during the 2nd quarter. ProShare Advisors LLC now owns 23,601 shares of the company's stock worth $192,000 after acquiring an additional 8,966 shares in the last quarter. Stanley Laman Group Ltd. boosted its stake in shares of Adaptive Biotechnologies by 7.8% during the 2nd quarter. Stanley Laman Group Ltd. now owns 114,780 shares of the company's stock worth $929,000 after acquiring an additional 8,288 shares in the last quarter. Manchester Capital Management LLC purchased a new stake in shares of Adaptive Biotechnologies in the first quarter valued at $43,000. Finally, Hedeker Wealth LLC purchased a new stake in shares of Adaptive Biotechnologies in the second quarter valued at $1,063,000. 93.49% of the stock is owned by institutional investors.
其他大型投資者也修改了持有該公司的股份。新澤西州共同養老基金D在第二季度將其在Adaptive Biotechnologies的股份增加了58.4%。新澤西州共同養老基金D在上個季度又收購了108,686股股票後,現在擁有該公司294,645股股票,價值238.4萬美元。ProShare Advisors LLC在第二季度將其在Adaptive Biotechnologies的股份增加了61.3%。ProShare Advisors LLC在上個季度又收購了8,966股股票後,現在擁有該公司23,601股股票,價值19.2萬美元。斯坦利·拉曼集團有限公司在第二季度將其在Adaptive Biotechnologies的股份增加了7.8%。Stanley Laman Group Ltd.在上個季度又收購了8,288股股票後,現在擁有該公司114,780股股票,價值92.9萬美元。曼徹斯特資本管理有限責任公司在第一季度購買了Adaptive Biotechnologies的新股份,價值43,000美元。最後,Hedeker Wealth LLC在第二季度購買了Adaptive Biotechnologies的新股份,價值1,06.3萬美元。該股的93.49%歸機構投資者所有。
Insider Activity
內幕活動
In other news, insider Nitin Sood sold 31,066 shares of the firm's stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $8.00, for a total value of $248,528.00. Following the sale, the insider now directly owns 114,505 shares of the company's stock, valued at $916,040. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 35,150 shares of company stock valued at $279,719. 4.20% of the stock is owned by insiders.
在其他新聞方面,內部人士尼廷·蘇德在11月1日星期二的交易中出售了該公司31,066股股票。該股的平均價格爲8.00美元,總價值爲248,528.00美元。出售後,該內部人士現在直接擁有該公司114,505股股票,價值916,040美元。此次出售是在向美國證券交易委員會提交的一份文件中披露的,該文件可在以下網址查閱 美國證券交易委員會網站。在過去的九十天裏,內部人士出售了價值279,719美元的35,150股公司股票。4.20%的股票歸內部人士所有。
Wall Street Analysts Forecast Growth
華爾街分析師預測增長
Adaptive Biotechnologies Price Performance
自適應生物技術價格表現
Adaptive Biotechnologies stock opened at $7.86 on Wednesday. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -5.04 and a beta of 1.05. Adaptive Biotechnologies Co. has a one year low of $5.95 and a one year high of $30.51. The company's fifty day moving average price is $7.54 and its two-hundred day moving average price is $8.46.
適應性生物技術股票週三開盤價爲7.86美元。該公司的市值爲11.2億美元,市盈率爲-5.04,beta爲1.05。Adaptive Biotechnologies Co. 創一年低點5.95美元,一年高點爲30.51美元。該公司的五十天移動平均線價格爲7.54美元,其兩百天移動平均線價格爲8.46美元。
Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. The company had revenue of $47.80 million for the quarter, compared to the consensus estimate of $48.41 million. Adaptive Biotechnologies had a negative return on equity of 40.95% and a negative net margin of 131.81%. The firm's revenue was up 21.0% compared to the same quarter last year. During the same period last year, the business posted ($0.40) earnings per share. As a group, sell-side analysts anticipate that Adaptive Biotechnologies Co. will post -1.51 earnings per share for the current year.
Adaptive Biotechnologies(納斯達克股票代碼:ADPT — 獲取評級)最後一次發佈季度財報是在11月3日星期四。該公司公佈了本季度每股收益(0.32美元),比市場普遍預期的(0.37美元)高出0.05美元。該公司本季度的收入爲4,780萬美元,而市場普遍預期爲4,841萬美元。Adaptive Biotechnologies的股本回報率爲負40.95%,淨利潤率爲負131.81%。與去年同期相比,該公司的收入增長了21.0%。去年同期,該公司公佈了每股收益(0.40美元)。整體而言,賣方分析師預計,Adaptive Biotechnologies Co. 本年度的每股收益將爲-1.51。
Adaptive Biotechnologies Profile
自適應生物技術概況
(Get Rating)
(獲取評級)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection.
Adaptive Biotechnologies Corporation是一家處於商業階段的公司,它開發了一個用於診斷和治療各種疾病的免疫醫學平台。該公司提供 ImmunoSeq,這是一種平台和核心免疫測序產品,用於回答轉化研究問題以及發現新的預後和診斷信號;還提供 T-Detect COVID,用於確認過去 COVID-19 感染。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Adaptive Biotechnologies (ADPT)
- Which Stocks Are Black Friday, Cyber Monday Winners & Losers?
- Three Reasons It's Time To Get Bullish On Organigram
- Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
- Why Investors Are Eating Up Restaurant Brands International
- Zoom Video Continues to Work Through Normalization
- 免費獲取 StockNews.com 關於適應性生物技術 (ADPT) 的研究報告
- 哪些股票是黑色星期五、網絡星期一的贏家和輸家?
- 是時候看好 Organigram 的三個原因了
- 機會來襲!Hibbett, Inc. 因業績強勁而持平
- 爲什麼投資者正在吞噬國際餐廳品牌
- Zoom 視頻通過標準化繼續發揮作用
Want to see what other hedge funds are holding ADPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Rating).
想看看還有哪些對沖基金持有ADPT嗎? 訪問 HoldingSchannel.com 獲取Adaptive Biotechnologies Co. 的最新13F申報和內幕交易(納斯達克股票代碼:ADPT — 獲取評級)。
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收自適應生物技術的新聞和評級 -在下面輸入您的電子郵件地址,即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Adaptive Biotechnologies及相關公司的最新新聞和分析師評級的簡明每日摘要。